http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013135662-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2012-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013135662-A |
| titleOfInvention | SUBSTITUTED QUINOLINE COMPOUNDS AND METHODS OF USE THEREOF |
| abstract | 1. The compound of formula (I): or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically approved salt or a prodrug thereof, wherein: each of R and R are independently H, alkoxy or hydroxyalkoxy; R is H or F; R is H, F, Cl, Br, I, CN, alkyl, haloalkyl or heterocyclyl, heterocyclylalkyl, cycloalkyl, or cycloalkylalkyl; and X is CH or N, where at least one of R and R is hydroxyalkoxy. 2. The compound according to claim 1, where R is hydroxy Calkoxy; R is H or F; R is H or methoxy; and R is H, F, Cl, Br, I, CN, Haloalkyl, Heterocyclyl C1-6alkyl, Cycloalkyl or Cycloalkyl C1-6alkyl. 3. The compound according to claim 1, where R is hydroxy Salkoxy; R is H or methoxy; R is H or F; R is H or F; X is CH.4. The compound according to claim 1, where R is hydroxy Salkoxy; R is H; R is H or F; R is H; and H is CH.5. A compound of formula 1 having one of the following structures: or stereoisomer, geometric isomer, tautomer, N-oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof. 6. A pharmaceutical composition comprising a compound according to any one of paragraphs. 1-5 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, medium, or a combination thereof. 7. The pharmaceutical composition according to claim 6, further comprising a therapeutic agent selected from a chemotherapeutic drug, an antiproliferative drug for treating atherosclerosis, a drug for treating pulmonary fibrosis and a combination thereof. The pharmaceutical composition according to claim 7, where the additional therapeutic agent is adriamycin, rapamycin, temsirolimus, |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10934274-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2750727-C2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2750727-C9 |
| priorityDate | 2011-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 127.